socalTECH

DECEMBER 17, 2013

Thousand Oaks-based biopharmaceuticals startup Atara Biotherapeutics announced this morning that it has raised $38.5M in a Series B funding round, for its efforts to develop treatments for patients with end-stage renal disease.

Thousand Oaks 180

Thousand Oaks Venture Capital Capital Funding 180

socalTECH

OCTOBER 12, 2016

Thousand Oaks-based Akriveia Therapeutics , a biotechnology startup focused on immuno-oncology, announced this morning that it has raised $7.5M Akriveia Therapeutics said it is developing immunotherapeutic products that are specifically activated in the microenvironment of the tumor. in a Series A investment.

Thousand Oaks 100

Thousand Oaks Research Activity Invest 100

socalTECH

OCTOBER 9, 2015

Thousand Oaks-based Amgen has seen an exit out of its startup investment portfolio, and activities of its Amgen Ventures venture capital arm, at Berkeley-based Adheron Therapeutics this morning. Adheron said that it has been acquired by Roche , in a deal worth $105M upfront and up to $475M in additional milestone payments.

Thousand Oaks 100

Thousand Oaks Venture Capital Activity Capital 100

socalTECH

FEBRUARY 21, 2013

Xirrus , the wireless hardware provider based in Thousand Oaks, has just raised $10.1M in a funding round, part of an ongoing $11.0M funding, according to a regulatory filing by the company. Details on the funding have not yet been announced by the company.

Thousand Oaks 164

Thousand Oaks Conference Networking Capital 164

socalTECH

APRIL 29, 2014

We caught up with one of the local teams competing in that competition, VOXearch (www.voxearch.com), to learn more about the prize as well as their specific approach to the competition. Mike Outmesguine: We''re one of about thirty teams left in the challenge, out of more than 300 that signed up last August.

Startup 262

Startup Competition Software Review UCLA 262

Xconomy

JULY 22, 2016

But there’s plenty more to dig through as well, from a shakeup at Zafgen to a few new high profile startups and a newly public gene therapy company. —Celgene (NASDAQ: CELG ), of Summit, NJ, inked its latest immuno-oncology deal, forming a wide-ranging alliance with Cambridge-based Jounce Therapeutics to develop a group of cancer drugs.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

JUNE 10, 2016

Guardant is funding a series of trials around the country in people whose genetic or lifestyle profiles put them at high risk of five types of cancer. As the conference wrapped up, a Morgan Stanley analyst noted that Pfizer the previous week had raised its drug prices nine percent, continuing a regular pattern of price increases.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67

Xconomy

AUGUST 26, 2016

Mylan bumped up the price of the EpiPen 400 percent, presidential nominee Hillary Clinton responded with a tirade against drug price hikes, and—much like when Clinton railed against drug pricing last year—biotech indexes promptly plummeted more than 3 percent. —Pfizer wasn’t done after scooping up Medivation.

Pricing 40

Pricing Thousand Oaks Startup Research 40